Posts

Microneedle Vaccine Patch Company Funding and Development

Micron Biomedical, an Atlanta-based biotech company, secured an additional $3 million investment from J2 Ventures, bringing their Series A round total to $17 million The company was founded in 2014 by Mark Prausnitz, Devin McAllister, and Sebastien Henry to develop dissolvable microneedle patch technology for vaccine delivery Micron Biomedical's vaccine patch uses biocompatible polymer microneedles that dissolve after insertion, enabling painless vaccine delivery through the skin The technology eliminates the need for refrigeration and needle disposal, reducing vaccine distribution costs and complexity The company is developing vaccine patches for COVID-19, cancer, and other chronic diseases, with the technology currently in the development phase showing promising preclinical results The Series A round was initiated in November 2022 and led by Global Health Investment Corporation (GHIC) and LTS Lohmann with participation from GRA Venture Fund Dr. Matt Goldman from J2 Ve...

Merck to Acquire Terns Pharmaceuticals for $6.7 Billion, Betting on TERN-701 to Challenge Novartis' Scemblix in CML

The Oncology Market: Outlook for 2026

Novo Nordisk's Triple-G Agonist UBT251 Achieves 19.7% Weight Loss in Phase 2 Trial in China

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

Merck Collaborates with Quotient Therapeutics on Inflammatory Bowel Disease Drug Discovery Using Somatic Genomics Platform

Ocugen Advances Gene Therapy Programs for Retinal Diseases with Phase 3 Trials

Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Scientific Advisory Board

Tecan Proposes Board Changes for 2026 AGM: New Chairman and Three Directors

QuantHealth Bolsters Executive Leadership Team to Support Expanding Product Portfolio and Growing Client Footprint

QT Imaging Receives UAE Regulatory Clearance for Breast Acoustic CT Scanner

Galaxy Brain Scientific's SCAN-Targeted Technology Redefines Parkinson's Treatment Through Precision Neural Circuit Stimulation

FDA Approves Opdivo (Nivolumab) for Classical Hodgkin Lymphoma Indications